Galmed Pharmaceuticals Ltd. (GLMD)

NASDAQ: GLMD · Real-Time Price · USD

0.589

-0.035 (-5.58%)

At close: Apr 28, 2026, 4:00 PM EDT

0.546

-0.043 (-7.32%)

After-hours: Apr 28, 2026, 7:58 PM EDT

Galmed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	3.64	3.3	3.92	4.66	5.66	Upgrade
Research & Development	4.87	2.98	3.57	13	27.22	Upgrade
Operating Expenses	8.51	6.28	7.49	17.65	32.88	Upgrade
Operating Income	-8.51	-6.28	-7.49	-17.65	-32.88	Upgrade
Interest Expense	-0.08	-0.61	-	-	-	Upgrade
Interest & Investment Income	0.91	0.5	0.38	0.3	0.56	Upgrade
Currency Exchange Gain (Loss)	-0.08	0.04	-0.04	0.04	-0.03	Upgrade
Other Non Operating Income (Expenses)	-0.02	-0.02	0.25	-0.02	-0.04	Upgrade
EBT Excluding Unusual Items	-7.77	-6.36	-6.9	-17.34	-32.39	Upgrade
Gain (Loss) on Sale of Investments	-2.54	-1.16	-0.01	-0.53	-0.08	Upgrade
Pretax Income	-10.31	-7.52	-6.91	-17.87	-32.47	Upgrade
Net Income	-10.31	-7.52	-6.91	-17.87	-32.47	Upgrade
Net Income to Common	-10.31	-7.52	-6.91	-17.87	-32.47	Upgrade
Shares Outstanding (Basic)	4	1	0	0	0	Upgrade
Shares Outstanding (Diluted)	4	1	0	0	0	Upgrade
Shares Change (YoY)	363.17%	303.31%	65.23%	2.22%	15.59%	Upgrade
EPS (Basic)	-2.39	-8.08	-29.95	-127.90	-237.59	Upgrade
EPS (Diluted)	-2.39	-8.08	-29.95	-127.90	-237.59	Upgrade
Free Cash Flow	-6.32	-5.88	-6.14	-18.51	-32.9	Upgrade
Free Cash Flow Per Share	-1.47	-6.32	-26.59	-132.48	-240.78	Upgrade
EBITDA	-8.43	-6.2	-7.46	-17.62	-32.84	Upgrade
D&A For EBITDA	0.08	0.08	0.03	0.04	0.04	Upgrade
EBIT	-8.51	-6.28	-7.49	-17.65	-32.88	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.